TCG Crossover Management LLC Purchases 137,380 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

TCG Crossover Management LLC grew its stake in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 13.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,145,538 shares of the company's stock after purchasing an additional 137,380 shares during the period. Kodiak Sciences comprises about 1.1% of TCG Crossover Management LLC's investment portfolio, making the stock its 29th biggest position. TCG Crossover Management LLC owned about 2.18% of Kodiak Sciences worth $11,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Kodiak Sciences by 10,982.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company's stock valued at $12,622,000 after acquiring an additional 1,257,063 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Kodiak Sciences during the fourth quarter worth about $11,338,000. Silverarc Capital Management LLC boosted its holdings in Kodiak Sciences by 100.0% during the fourth quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company's stock valued at $9,950,000 after purchasing an additional 500,000 shares in the last quarter. Invesco Ltd. grew its stake in shares of Kodiak Sciences by 545.7% in the 4th quarter. Invesco Ltd. now owns 519,010 shares of the company's stock valued at $5,164,000 after purchasing an additional 438,635 shares during the period. Finally, Nantahala Capital Management LLC increased its position in shares of Kodiak Sciences by 287.2% during the 4th quarter. Nantahala Capital Management LLC now owns 266,613 shares of the company's stock worth $2,653,000 after purchasing an additional 197,756 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Kodiak Sciences Trading Up 6.9 %

NASDAQ KOD traded up $0.31 on Friday, hitting $4.80. 615,630 shares of the company were exchanged, compared to its average volume of 344,350. Kodiak Sciences Inc. has a 1-year low of $1.92 and a 1-year high of $11.60. The firm has a 50 day moving average of $3.27 and a two-hundred day moving average of $5.47. The company has a market cap of $253.21 million, a P/E ratio of -1.32 and a beta of 2.40.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06. Research analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.